Dermata Therapeutics Inc(DRMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DRMA Dermata Therapeutics Inc

Market Closed 06-26 16:00:00 EDT

1.29

+0.12

+10.26%

盘后1.24

-0.05-3.78%

19:56 EDT

High1.33	Low1.18	Vol263.49K
Open1.18	D1 Closing1.17	Amplitude12.83%
Mkt Cap5.19M	Tradable Cap3.59M	Total Shares4.02M
T/O330.79K	T/O Rate9.46%	Tradable Shares2.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DRMA","market":"US","secType":"STK","nameCN":"Dermata Therapeutics Inc","latestPrice":1.29,"timestamp":1782504000000,"preClose":1.17,"halted":0,"volume":263488,"hourTrading":{"tag":"盘后","latestPrice":1.2412,"preClose":1.29,"latestTime":"19:56 EDT","volume":799,"amount":991.5208,"timestamp":1782518205454,"change":-0.0488,"changeRate":-0.037829,"amplitude":0.046512},"delay":0,"changeRate":0.10256410256410266,"floatShares":2784800,"shares":4022100,"eps":-4.033191,"marketStatus":"Market Closed","change":0.12,"latestTime":"06-26 16:00:00 EDT","open":1.1799,"high":1.33,"low":1.1799,"amount":330789.44874880003,"amplitude":0.128291,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.033191,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782720000000},"marketStatusCode":7,"adr":0,"listingDate":1628827200000,"exchange":"NASDAQ","adjPreClose":1.17,"preHourTrading":{"tag":"盘前","latestPrice":1.2252,"preClose":1.17,"latestTime":"08:55 EDT","volume":66,"amount":81.1752018,"timestamp":1782478552330,"change":0.0552,"changeRate":0.047179,"amplitude":0.004103},"postHourTrading":{"tag":"盘后","latestPrice":1.2412,"preClose":1.29,"latestTime":"19:56 EDT","volume":799,"amount":991.5208,"timestamp":1782518205454,"change":-0.0488,"changeRate":-0.037829,"amplitude":0.046512},"volumeRatio":4.726394118701811},"requestUrl":"/m/hq/s/DRMA","defaultTab":"news","newsList":[{"id":"2644608737","title":"Dermata Therapeutics director Kathleen D. Scott disposes of 11 common shares worth $13.09","url":"https://stock-news.laohu8.com/highlight/detail?id=2644608737","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644608737?lang=en_us&edition=fundamental","pubTime":"2026-06-17 04:16","pubTimestamp":1781640981,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics director Kathleen D. Scott sold 11 shares of common stock on June 16, 2026 at $1.19.She reported 1 share held indirectly through the Scott 2008 Trust dated March 28, 2008.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL4bPdvj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Dermata Therapeutics director Kathleen D. Scott disposes of 11 common shares worth $13.09","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4007","DRMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638663438","title":"Dermata Therapeutics Shareholders Approve Equity Plan and Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2638663438","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638663438?lang=en_us&edition=fundamental","pubTime":"2026-05-28 06:09","pubTimestamp":1779919742,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics ( ($DRMA) ) just unveiled an update. On May 27, 2026, Dermata Therapeutics held its 2026 Annual Meeting of Stockholders, where...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dermata-therapeutics-shareholders-approve-equity-plan-and-directors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dermata-therapeutics-shareholders-approve-equity-plan-and-directors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4585","EQR","BK4539","BK4588","BK4139","DRMA","BK4215"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638463959","title":"Dermata Therapeutics shareholders approved equity plan share increase to 402,214 at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2638463959","media":"Reuters","labels":["executive","shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638463959?lang=en_us&edition=fundamental","pubTime":"2026-05-28 04:58","pubTimestamp":1779915497,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics held its annual shareholder meeting on May 27, 2026.Shareholders authorized an amendment to the 2021 Omnibus Equity Incentive Plan, lifting the share pool to 402,214 shares.Investors also backed the planned issuance of common stock underlying certain warrants tied to a December 23, 2025 securities purchase agreement.Approval was also granted to reprice warrants exercisable for up to 120,734 common shares.CBIZ CPAs was ratified as independent auditor for the year ending Dec. 31, 2026; an adjournment proposal was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDLRX6pV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","DRMA","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636986145","title":"Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4","url":"https://stock-news.laohu8.com/highlight/detail?id=2636986145","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636986145?lang=en_us&edition=fundamental","pubTime":"2026-05-20 03:45","pubTimestamp":1779219938,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Dermata Therapeutics, with a price target of $4.00. An...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-dermata-keeps-12-month-price-target-unchanged-at-4-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-dermata-keeps-12-month-price-target-unchanged-at-4-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","BK4007","DRMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635756164","title":"Dermata Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635756164","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635756164?lang=en_us&edition=fundamental","pubTime":"2026-05-14 05:01","pubTimestamp":1778706069,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryDermata Therapeutics Inc DRMA.OQ reported a quarterly adjusted loss of $1.52 per share for the quarter ended M","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q2UG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635756351","title":"Dermata Therapeutics Q1 EPS $(0.48) Beats $(0.53) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635756351","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635756351?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:48","pubTimestamp":1778705326,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.53) by 9.43 percent. This is a 89.33 percent increase over losses of $(4.50) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52545653/dermata-therapeutics-q1-eps-0-48-beats-0-53-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Dermata Therapeutics Q1 EPS $(0.48) Beats $(0.53) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758748","title":"Dermata net loss narrows to USD 1.85 million in Q1 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758748","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758748?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:08","pubTimestamp":1778702926,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics posted Q1 net loss of USD 1.85 million, narrowing from USD 2.3 million a year earlier; loss per share improved to USD 0.48 from USD 4.47.Operating loss narrowed to USD 1.93 million from USD 2.34 million, while operating expenses fell to USD 1.93 million from USD 2.34 million.Research and development expense dropped to USD 384,000 from USD 1.28 million, while selling, general and administrative costs climbed to USD 1.54 million from USD 1.06 million.Cash and cash equivalents slid to USD 6.95 million at March 31 from USD 7.52 million at Dec. 31, after raising USD 2 million in net proceeds from an at-the-market facility.Dermata outlined a mid-2026 launch for Tome Foundational Treatment, a once-weekly direct-to-consumer mask for skin renewal, with work under way on packaging, website buildout and consumer use studies.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL59mBKm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4007","DRMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634460631","title":"Dermata Therapeutics Inc  expected to post a loss of 53 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634460631","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634460631?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:53","pubTimestamp":1778277185,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc  expected to post a loss of53cents a share - Earnings Preview Dermata Therapeutics Inc DRMA.OQ DRMA.O is expected to  report resultson May 12 (estimated) for the period ending","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L2QE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","DRMA","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625886931","title":"Dermata Therapeutics announces annual shareholder meeting webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2625886931","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625886931?lang=en_us&edition=fundamental","pubTime":"2026-04-07 18:01","pubTimestamp":1775556115,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics annual shareholder meeting set for May 27, 2026 in virtual format.Shareholders to vote on election of three Class II directors for terms running to 2029.Ballot includes ratification of CBIZ CPAs as independent auditor for fiscal 2026.Company seeking approval to issue common shares underlying warrants from December 2025 financing, potentially exceeding 20% of shares outstanding at issuance.Items also include repricing warrants covering 120,734 shares, increase in 2021 equity plan share reserve to 402,214 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval syst","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL6xXtJv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","DRMA","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624509163","title":"Dermata says Australian patent application for topical dermal fillers accepted for Bioneedle system","url":"https://stock-news.laohu8.com/highlight/detail?id=2624509163","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624509163?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:32","pubTimestamp":1775133174,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics received acceptance from Australian Patent Office for patent application covering topical delivery of dermal fillers using its Bioneedle Delivery System.Patent, titled “Compositions for the treatment of conditions by dermal fillers,” is set to issue in about three months unless a third party files an opposition.Dermata already holds allowed or issued patents in US, Australia, Japan covering Bioneedle Delivery System with botulinum toxin for hyperhidrosis treatment.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDLLDKB1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DRMA","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624758515","title":"Dermata Therapeutics price target lowered to $4 from $10 at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2624758515","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624758515?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:35","pubTimestamp":1775046912,"startTime":"0","endTime":"0","summary":"Maxim lowered the firm’s price target on Dermata Therapeutics (DRMA) to $4 from $10 and keeps a Buy rating on the shares. The company’s Q4 results ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-price-target-lowered-to-4-from-10-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-price-target-lowered-to-4-from-10-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DRMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622891421","title":"Dermata Therapeutics Q4 EPS $(1.52) Beats $(1.54) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622891421","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622891421?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:18","pubTimestamp":1774559921,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(1.52) per share which beat the analyst consensus estimate of $(1.54) by 1.3 percent. This is a 83.48 percent increase over losses of $(9.20) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51497892/dermata-therapeutics-q4-eps-1-52-beats-1-54-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Dermata Therapeutics Q4 EPS $(1.52) Beats $(1.54) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622891491","title":"Dermata Therapeutics FY2025 net loss narrows 38.5% to $7.6 million; cash and cash equivalents climb 138% to $8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622891491","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622891491?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:17","pubTimestamp":1774559838,"startTime":"0","endTime":"0","summary":"Dermata filed a Form 8-K reporting full-year 2025 results, including a net loss of USD 7.6 million.Research and development expense fell 64.27% to USD 2.9 million, primarily due to lower clinical costs after completion of the STAR-1 acne study in Q2 2025.Selling, general and administrative expense rose 12.42% to USD 4.8 million, driven mainly by USD 0.7 million in marketing expense.Cash and cash equivalents were USD 7.5 million as of Dec. 31, 2025, and the company said its cash resources are expected to fund operations into Q1 2027.Management said Dermata is pivoting to direct-to-consumer skincare under the Tome brand, with a first product launch targeted for mid-2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL2J3K1X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620040681","title":"Dermata Therapeutics SVP Regulatory Affairs Maria E Bedoya-Toro Munera acquires USD 1,270 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620040681","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620040681?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:44","pubTimestamp":1773783897,"startTime":"0","endTime":"0","summary":"Maria Bedoya-Toro Munera, SVP of Regulatory Affairs at Dermata Therapeutics, reported the acquisition of 1,000 common shares at USD 1.27 per share. Following the transaction, she reported direct beneficial ownership of 1,012 common shares. She also reported indirect beneficial ownership of 34 common shares held through the Munera Family Trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL9kNvFw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Dermata Therapeutics SVP Regulatory Affairs Maria E Bedoya-Toro Munera acquires USD 1,270 in common shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4007","DRMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619143637","title":"Dermata Therapeutics Inc  expected to post a loss of $1.54 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2619143637","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619143637?lang=en_us&edition=fundamental","pubTime":"2026-03-14 05:14","pubTimestamp":1773436446,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc  expected to post a loss of $1.54 a share - Earnings Preview Dermata Therapeutics Inc DRMA.OQ DRMA.O is expected to  report resultson March 17 (estimated) for the period endin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL8N401256:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618958532","title":"Dermata Therapeutics appoints Kyra Peckaitis as VP of Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2618958532","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618958532?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:30","pubTimestamp":1773145814,"startTime":"0","endTime":"0","summary":"Dermata appointed Kyra Peckaitis as vice president of marketing to lead the launch of its Tome skincare brand. Peckaitis previously served as associate director of brand marketing at Coterie. She also held roles on HubSpot’s global brand team and at Sweetgreen’s integrated marketing team.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief on March 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL74GBns:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9Z06.USD","LU2054465674.USD","BK4209","LU2095319765.USD","IE00B19Z9P08.USD","SG","DRMA","IE00BMPRXN33.USD","BK4539","BK4023","LU2210149790.SGD","BK4585","IE00B894F039.SGD","BK4613","BK4139","BK4528","BK4588","LU2210150020.SGD","IE00BZ9MQY76.HKD","BK4007","HUBS","IE00BMPRXR70.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617287955","title":"Dermata Therapeutics Unveils Tome Skincare Line","url":"https://stock-news.laohu8.com/highlight/detail?id=2617287955","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617287955?lang=en_us&edition=fundamental","pubTime":"2026-03-05 22:00","pubTimestamp":1772719214,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc. announced the branding of its new consumer skincare line, Tome, positioning it as “skintech at home” and part of a strategic shift toward becoming a consumer-facing company. The company said it expects to launch its first Tome product, an over-the-counter once-weekly acne and resurfacing treatment, in mid-2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL2TvWFh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","BK4139","DRMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614405621","title":"Dermata Therapeutics Director Mary Fisher Resigns Effective March 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2614405621","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614405621?lang=en_us&edition=fundamental","pubTime":"2026-02-26 05:14","pubTimestamp":1772054076,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc. said director Mary Fisher will resign from its board and all committee roles effective March 31, 2026. The company said her departure is not due to any disagreement and is related to her employer’s recent acquisition, which no longer allows her to serve on the board. The board will be reduced to seven members from eight.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 25, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDLfzD1C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","BK4139","DRMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605044876","title":"Dermata Therapeutics files to sell 1.48M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2605044876","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605044876?lang=en_us&edition=fundamental","pubTime":"2026-01-23 06:05","pubTimestamp":1769119525,"startTime":"0","endTime":"0","summary":"17:03 EST Dermata Therapeutics (DRMA) files to sell 1.48M shares of common stock for holders Published first on TheFly – the ultimate source for re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-files-to-sell-1-48m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-files-to-sell-1-48m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","DRMA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604115862","title":"Dermata Therapeutics Granted Australian Patent for Spongilla-Based Acne Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2604115862","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604115862?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:07","pubTimestamp":1768914462,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc. has announced that the Australian Patent Office has granted its patent for a Spongilla technology combination as a method for treating acne. The patent, titled \"Compositions and methods for the treatment of skin conditions\" , follows a previously issued U.S. patent for the same technology. This development further strengthens Dermata's international intellectual property portfolio for its acne treatment innovations as the company prepares for the future launch of its once-weekly, over-the-counter acne treatment system. Additional patent applications are pending in other key markets.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this new","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL8PSjS8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","DRMA","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dermatarx.com;ir.dermatarx.com","stockEarnings":[{"period":"1week","weight":0.1026},{"period":"1month","weight":-0.0077},{"period":"3month","weight":0.0932},{"period":"6month","weight":-0.3065},{"period":"1year","weight":-0.7799},{"period":"ytd","weight":-0.444}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.070436},{"month":2,"riseRate":0,"avgChangeRate":-0.221628},{"month":3,"riseRate":0.4,"avgChangeRate":-0.164591},{"month":4,"riseRate":0.4,"avgChangeRate":-0.040018},{"month":5,"riseRate":0,"avgChangeRate":-0.135458},{"month":6,"riseRate":0.2,"avgChangeRate":-0.14152},{"month":7,"riseRate":0.25,"avgChangeRate":-0.133285},{"month":8,"riseRate":0.25,"avgChangeRate":-0.03319},{"month":9,"riseRate":0,"avgChangeRate":-0.128292},{"month":10,"riseRate":0.4,"avgChangeRate":-0.136086},{"month":11,"riseRate":0.2,"avgChangeRate":-0.072999},{"month":12,"riseRate":0.2,"avgChangeRate":-0.194478}],"exchange":"NASDAQ","name":"Dermata Therapeutics Inc","nameEN":"Dermata Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Dermata Therapeutics Inc(DRMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Dermata Therapeutics Inc(DRMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Dermata Therapeutics Inc,DRMA,Dermata Therapeutics Inc股票,Dermata Therapeutics Inc股票老虎,Dermata Therapeutics Inc股票老虎国际,Dermata Therapeutics Inc行情,Dermata Therapeutics Inc股票行情,Dermata Therapeutics Inc股价,Dermata Therapeutics Inc股市,Dermata Therapeutics Inc股票价格,Dermata Therapeutics Inc股票交易,Dermata Therapeutics Inc股票购买,Dermata Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Dermata Therapeutics Inc(DRMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Dermata Therapeutics Inc(DRMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction